regulatory affairs-introduction to ctd
TRANSCRIPT
![Page 1: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/1.jpg)
01/16/15 1
Drug Regulatory Affairs
By, Mahesh Shinde
The Bridge BetweenPharma Companies & Govt.
Agency
![Page 2: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/2.jpg)
2
Regulatory affairs
• It is by no means boring! It’s interesting.
![Page 3: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/3.jpg)
3
Role of Regulatory Affairs
What is this?
![Page 4: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/4.jpg)
4
Regulatory System
YES YES YES
YES
YES
YES
Govt. Prescriber Distributor Patient
Govt.
Prescriber
Distributor
Patient
![Page 5: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/5.jpg)
5
• Drug = medicinal product
= pharmaceutical product
![Page 6: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/6.jpg)
6
Drug regulatory affairsAny activity with drugs
By whom? (the authority)
no (=does not belong to drug regulatory affairs)
yes
Prior authorisation needed?
Based on which (objective and subjective) criteria?
Subject to regular control (quality, inspection)?
By whom? (the authority)Based on which (objective and subjective) criteria?
![Page 7: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/7.jpg)
7
Activities with drugs…
• research (chemical, biological)• clinical trials on human beings• manufacture• registration – evaluation– authorisation
• (wholesale) distribution
continued
![Page 8: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/8.jpg)
8
Activities with drugs (cont’d)
• pricing• prescribing• reimbursement/subsidy• advertising (if any)• special control (e.g. narcotics)• post-marketing surveillance– national drug quality control lab– adverse effect reporting system
• (retail) distribution• etc.
poppy
![Page 9: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/9.jpg)
Quality = Quality of Personnel (Qualification, Training…)
+ Quality of Materials (Specifications, Approved Suppliers...)
+ Quality of Means (Qualified equipment's, maintenance…)
+ Quality of Media (GMP premises, Controlled environment…)
+ Quality of Methods (Calibration, Validation…)
Composition of Quality
9
QUALITYQUALITY
Raw Materials
Personnel
Procedures
Validated processes
EquipmentPremises
Environment
Packing Materials
![Page 10: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/10.jpg)
Functions of a Quality UnitFunctions of a Quality Unit
10
Quality Control
– Sampling and testing of components Raw materials,
Packing materials, intermediates and finished
products
– Compliance to Good Laboratory Practices (GLPs)
![Page 11: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/11.jpg)
Functions of a Quality UnitFunctions of a Quality Unit
11
Quality Assurance
– Designing robust quality systems
– Ensure compliance to relevant
regulatory requirements
– Ensure compliance to
requirements of Good
Manufacturing Practices (GMP)
![Page 12: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/12.jpg)
Value addition in QA functionValue addition in QA function
12
Quality Assurance:
– Perform structured self-inspection
audits at regular intervals to prevent
any failure or non-conformance
– Critically analyze the quality non-
conformance issues and suggest
corrective and preventive actions
![Page 13: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/13.jpg)
Value addition in QA function
13
Quality Assurance:
– Perform documentation audit to
ensure realistic recording of all the
relevant process parameters
– Review the adequacy of in-process
control checks to prevent any
potential failures
![Page 14: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/14.jpg)
Value addition in QA function
14
Quality Assurance:– Training & Knowledge Management
– Perform literature survey of FDA /
ICH / ISO guidelines, revisions in the
Pharmacopoeial specifications and the
current regulatory requirements and
provide training to the production
personnel.
![Page 15: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/15.jpg)
What is Dossier?
15
• Dossier is collection or file of documents that contains all the technical data of pharmaceutical product to be approved/ registered /marketed in country.
• It is commonly called as registration dossier.
In US : New Drug ApplicationIn EU : Marketing Authorization Application
![Page 16: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/16.jpg)
What is DMF?Drug Master File (DMF)
• US : United State Drug Master File (US-DMF)• EU : European Drug Master File (EDMF) or
Active Substance Master File (ASMF)
• TYPES OF DMFs• The types of DMFs are:• Type I - Manufacturing Site, Facilities, Operating Procedures, and Personnel (no
longer applicable)• Type II - Drug Substance, Drug Substance Intermediate, and Material Used in
Their Preparation, or Drug Product• Type III - Packaging Material• Type IV - Excipient, Colorant, Flavor, Essence, or Material Used in Their
Preparation• Type V - FDA Accepted Reference Information
16
![Page 17: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/17.jpg)
What is CTD/eCTD?Common Technical Documents (CTD)
• The Common Technical Document (CTD) is a set of specification for application dossier for the registration of Medicines and designed to be used across Europe, United States & ROW.
• Its electronic version called as Electronic Common Technical Document (eCTD)
17
![Page 18: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/18.jpg)
The CTD Triangle
18
![Page 19: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/19.jpg)
Module 1 Administrative & Prescribing Information (Region Specific):
Should Contain Documents specific to each region:
19
![Page 20: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/20.jpg)
Module 1 Administrative & Prescribing Information (Region Specific):
(1) SITE MASTER PLAN OF PLANT
(2) COMPANY PROFILE IN SHORT
(3) ATTESTED COPY OF MANUFACTURING LICENCE
(4) ATTESTED COPY OF PRODUCT PERMISSION FROM FDA
(5) ATTESTED COPY OF COPP
(6) ATTESTED COPY OF WHO/GMP CERTIFICATE
(7) COA OF SAMPLE
(8) ATTESTED COPY OF WHOLE SELL LICENCE.
(9) LETTER OF AUTHORISATION
20
![Page 21: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/21.jpg)
Module 2 CTD Summaries (QOS):
21
It contain 7 sections in the following order:
2.1 CTD Table of content (Module 2-5)2.1 CTD Table of content (Module 2-5)
2.2 CTD Introduction2.2 CTD Introduction
2.3 Quality Overall Summary 2.3 Quality Overall Summary
2.4 Non-Clinical Overview 2.4 Non-Clinical Overview
2.5 Clinical Overview2.5 Clinical Overview
2.6 Non-Clinical Summary2.6 Non-Clinical Summary
2.7 Clinical Summary2.7 Clinical Summary
![Page 22: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/22.jpg)
Module 3 Quality: Chemistry, Manufacturing & Controls (CMC)
22
3.1 Table of content (Module 3)3.1 Table of content (Module 3)
3.2 Body of Data3.2 Body of Data
3.2 S Drug Substance 3.2 S Drug Substance
3.2 S1 General Information (Name, Mfg.) 3.2 S1 General Information (Name, Mfg.)
3.2 S2 Manufacture3.2 S2 Manufacture
3.2 S3 Characterization 3.2 S3 Characterization
3.2 S4 Control of Drug Substance (Specification, Analytical procedures, Validation of Analytical procedures, etc. )
3.2 S4 Control of Drug Substance (Specification, Analytical procedures, Validation of Analytical procedures, etc. )
3.2 S5 Reference Standards3.2 S5 Reference Standards
3.2 S6 Stabil ity 3.2 S6 Stabil i ty
![Page 23: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/23.jpg)
Module 3 Quality: Chemistry, Manufacturing & Controls (CMC)
23
3.2 P Drug Product 3.2 P Drug Product
3.2 P1 Description and Composition of the Drug Product3.2 P1 Description and Composition of the Drug Product
3.2 P2 Pharmaceutical Development (name, dosage form)3.2 P2 Pharmaceutical Development (name, dosage form)
3.2 P3 Manufacturer3.2 P3 Manufacturer
3.2 P4 Control of Excipients3.2 P4 Control of Excipients
3.2 P5 Control of Drug Product (Specification, Analytical procedures, Validation of Analytical procedures, etc. )
3.2 P5 Control of Drug Product (Specification, Analytical procedures, Validation of Analytical procedures, etc. )
3.2 P6 Reference Standards3.2 P6 Reference Standards
3.2 P7 Stability 3.2 P7 Stability
![Page 24: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/24.jpg)
Module 3 Quality: Chemistry, Manufacturing & Controls (CMC)
24
3.2 A Appendices3.2 A Appendices
3.2 A1 Facility & Equipment's3.2 A1 Facility & Equipment's
3.2 A2 Advertising agents safety evaluation3.2 A2 Advertising agents safety evaluation
3.2 A3 Excipients3.2 A3 Excipients
3.2 R Regional Information3.2 R Regional Information
3.3 Literature References3.3 Literature References
![Page 25: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/25.jpg)
Module 4 Non-Clinical Study Reports:
25
4.1 Table of content (Module 4)4.1 Table of content (Module 4)
4.2 Study Reports4.2 Study Reports
4.2.1 Pharmacology4.2.1 Pharmacology
4.2.1. 1. Pharmacodynamics 4.2.1. 1. Pharmacodynamics
4.2.1. 2. Safety Pharmacology 4.2.1. 2. Safety Pharmacology
4.2.1. 3. Pharmacodynamics Drug Interaction 4.2.1. 3. Pharmacodynamics Drug Interaction
4.2.2 Pharmacokinetics4.2.2 Pharmacokinetics
4.2.2. 1. ADME 4.2.2. 1. ADME
4.2.2. 2. Pharmacokinetic Drug Interaction 4.2.2. 2. Pharmacokinetic Drug Interaction
4.2.2. 3. Other Pharmacokinetic Study 4.2.2. 3. Other Pharmacokinetic Study
![Page 26: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/26.jpg)
Module 4 Non-Clinical Study Reports:
26
4.2.3 Toxicology4.2.3 Toxicology
4.2.3. 1. Single/Repeat Dose Toxicity 4.2.3. 1. Single/Repeat Dose Toxicity
4.2.3. 2. Genotoxicity 4.2.3. 2. Genotoxicity
4.2.3. 3. In-Vivo/Vitro Toxicity 4.2.3. 3. In-Vivo/Vitro Toxicity
4.2.3. 4. Carcinogenicity 4.2.3. 4. Carcinogenicity
4.2.3. 5. Local Tolerance/Dependence 4.2.3. 5. Local Tolerance/Dependence
4.2.3. 6. Other Studies 4.2.3. 6. Other Studies
4.3 Literature References4.3 Literature References
![Page 27: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/27.jpg)
Module 5 Clinical Study Reports:
27
5.1 Table of content (Module 5)5.1 Table of content (Module 5)
5.2 Tabular listing of Clinical Studies 5.2 Tabular listing of Clinical Studies
5.3 Clinical study reports 5.3 Clinical study reports
5.3.1 Reports of Biopharmaceutical (BA-BE) Study 5.3.1 Reports of Biopharmaceutical (BA-BE) Study
5.3.2 Reports of Pharmacokinetic (biomaterial) study 5.3.2 Reports of Pharmacokinetic (biomaterial) study
5.3.3 Reports of Pharmacokinetic (PK) studies 5.3.3 Reports of Pharmacokinetic (PK) studies
5.3.4 Reports of Pharmacodynamics (PD) studies 5.3.4 Reports of Pharmacodynamics (PD) studies
5.3.4 Reports of Efficacy and Safety studies 5.3.4 Reports of Efficacy and Safety studies
5.3.4 Reports of Post-Marketing experience 5.3.4 Reports of Post-Marketing experience
5.3.4 Case Report Forms & Individual patient listings5.3.4 Case Report Forms & Individual patient listings
5.4 Literature References5.4 Literature References
![Page 28: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/28.jpg)
Sample
• Dossier • DMF
![Page 29: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/29.jpg)
Regulatory Compliance
National Regional Global
Regulatory Compliance
29
![Page 30: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/30.jpg)
National (India)
License Application Receipt
Manufacturing license Form No. 24 Form No. 25
Test license Form No. 30 Form No. 29
Import license Form No. 12 Form No.11
30
Compliance to (Drugs & Cosmetics Act 1940 & Rules under)
![Page 31: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/31.jpg)
National (India)
Drug Regulatory approval
Schedule Y ComplianceForm 44
Manufacturing Schedule M Compliance
Documentation Schedule U Compliance
Packaging Schedule P Compliance
API/Excipients/FP/PM IP Inputs if not BP/USP/ or IH
31
![Page 32: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/32.jpg)
Regulatory Dossier Regulatory approach:
Parameters US Europe Other markets India
API USP Ph.Eur. USP / Ph.Eur. IP
USDMF COS (CEP) / EDMF DMF requirement depends on the target market
Excipients USP Ph.Eur. USP / Ph.Eur. IP
Reference product US Europe Depends on the target market
Indian (if not available, then US or Europe)
Packaging materials
Complying to USP Ph.Eur. USP / Ph.Eur. IP
Finished product USP As per Ph.Eur. General requirement
USP / Ph.Eur. IP
Submission batch 1 2 2 or 3 -
Submission batch size
100,000 units or 1/10th of commercial
batch
100,000 units or 1/10th of
commercial batch
Depends on the target market
No such requirement
32
![Page 33: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/33.jpg)
Regulatory Dossier Regulatory approach:
Parameters US Europe Other markets India
Stability data 1 batch 2 batches 2 or 3 batches 3 batches
Stability condition Zone I & II condition Zone I & II condition Depends on the target market
Zone IV condition
Comparative dissolution study
3 media 3 media Depends on the target market
1 to 3 media
Input materials TSE/BSE, OVI statements
TSE/BSE Depends on the target market
No such requirement
Packaging materials Food grade certificate Food grade certificate Depends on the target market
No such requirement
Method validation data As per ICH ICH ICH No such guideline
Process validation data
Not required Not required Depends on the target market
Not required for submission
Bioequivalence study US reference product under fast and fed
condition
European reference product (generally
under fasting condition)
Generally fasting bio study
Fasting bio study
Bioequivalence study In USFDA approved CRO anywhere in the
world
MHRA/EU approved CRO anywhere
Depends on the target market
Indian study required
33
![Page 34: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/34.jpg)
Regulatory Authorities
India: DCGI & State Drug Administration European Union: MHRA USA : Food and Drug Administration (FDA) Australia : Therapeutic Goods Administration Newzeland : Medsafe South Africa: Medicines council control Japan : Ministry of Health & Labour Welfare Switzerland : Swissmedic Brazil : ANVISA (The National Health Surveillance Agency)
Mexico: COFEPRIS (The Federal Commission for the Protection against Sanitary Risk)
Chile : ISP - Instituto de Salud Pública de Chile Columbia: INVIMA – Instituto Nacional de Vigilancia de Medicamentos Alimentos Carrera 68 D No. 17 - 11 / 21 Argentina: ANMAT - set in 1992 Argentine National Administration of Drugs, Food & Medical TechnologyFrance: Agence Française de Sécurité Sanitaire des Produits de SantéGermany: Federal Institute for Drugs and Medical Devices
34
![Page 35: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/35.jpg)
Important sitesRegulatory sites:
www.fda.govwww.tga.gov.au http://www.emea.europa.eu/ www.ministeriodesalud.go.cr www.mspas.gob.gthttp://www.minsa.gob.pa/minsa2006/inicio.phphttp://www.minsa.gob.nihttp://www.salud.gob.hn/www.cssp.gob.svhttp://www.sns.gov.bo/http://www.inh.gov.ec/http://www.mspbs.gov.py/http://www.msp.gub.uy/index_1.htmlhttp://digemid.minsa.gob.pehttp://www.inhrr.gov.vehttp://pharmacos.eudra.org
35
![Page 36: Regulatory affairs-Introduction to CTD](https://reader034.vdocuments.site/reader034/viewer/2022042602/55a52b651a28ab6c678b47c7/html5/thumbnails/36.jpg)
Important sites
Useful links:
•www.usp.org •www.pheur.org •www.jpdb.nihs.go.jp •www.picscheme.org •www.pda.org •www.phrma.org •www.pharmacy.org •www.elsevier.com •www.ich.org•www.ijpsonline.com •www.pharmj.com •www.scripnews.com
36